araag2/HINT huggingface dataset:
Clinical trial NCT00520741 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lacosamide, lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a diagnosis of Epilepsy with Simple Partial Seizures (motor component) and
             or Complex Partial Seizures (with or without secondary generalization)

          -  Must be experiencing 2 to 40 seizures per 28-day period

          -  Stable dose of 1 or 2 marketed antiepileptic drugs

          -  Second Antiepileptic Drug (AED) must be less than or equal to 50 % of the minimum
             recommended maintenance dose per USA product label at screening

        Exclusion Criteria:

          -  Subject has a history of primary generalized or unclassified seizures

          -  Seizure disorder primarily characterized by isolated auras

          -  History of status epilepticus

          -  Seizures that are uncountable due to clustering

          -  Has greater than 5 seizures/day

          -  Subjects taking Benzodiazepines, Phenobarbital or Primidone

          -  Subject has Vagus Nerve Stimulation (VNS)

          -  Significant medical or psychiatric condition

          -  History of alcohol or drug abuse

          -  History of Ethosuximide use, Felbamate use after 1994 or Vigabatrin use after 1997
Clinical trial NCT01104792 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: cariprazine
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients and corresponding caregivers who have provided informed consents prior to any
             study specific procedures.

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
             disorganized type, catatonic type, or undifferentiated type), as confirmed by the
             Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (SCID).

          -  Patients with normal physical examination, laboratory, vital signs, and
             electrocardiogram (ECG).

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform
             disorder, bipolar I or bipolar II disorder, or psychotic disorders other than
             schizophrenia.
Clinical trial NCT00174733 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide (xrp1526)
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 12 years or older

          -  History of persistent bronchial asthma for at least 6 months

          -  Documented use of an inhaled steroid or a combination of an inhaled
             steroid/long-acting beta 2 agonist for at least 1 month before screening

          -  At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or
             ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml
             post-bronchodilator

          -  Be able to use oral inhalers

          -  Non-smokers

        Exclusion Criteria:

          -  History of life-threatening asthma

          -  Other pulmonary diseases; URI within 4 weeks before screening

          -  Use of systemic steroids within 1 month before screening or more than 3 times in
             previous 6 months

          -  Beta-adrenergic blocking agent use

          -  More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in
             the prior year before screening

          -  Pregnant or breast-feeding females

          -  Females of child-bearing potential not using adequate means of birth control

          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major
             systemic disease

          -  Abnormal clinical laboratory parameters that would limit participation in the study or
             interfere with interpretation of study results

          -  History of drug or alcohol abuse

          -  Treatment with any investigational product within 30 days prior to study entry
Clinical trial NCT00566982 (phase 3, status: completed)
Conditions: atrophy, vaginal diseases
ICD codes: H21.29, H31.23, H47.20, H47.22, N50.0, N64.2, N90.5
Drugs: ospemifene 60 mg, placebo
SMILES: OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Naturally or surgically menopausal

          -  Intact uterus

          -  Vaginal pH greater than 5.0

          -  5% or fewer superficial cells in maturation index of vaginal smear

        Exclusion Criteria:

          -  Evidence of endometrial hyperplasia, cancer or other pathology

          -  Abnormal Pap smear

          -  Uterine bleeding of unknown origin or uterine polyps

          -  Current vaginal infection requiring medication

          -  Use of hormonal medications

          -  Clinically significant abnormal gynecological findings other than signs of vaginal
             atrophy
Clinical trial NCT00091442 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, doxil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females with locally advanced or metastatic breast cancer who received prior
             anthracycline therapy in the neoadjuvant or adjuvant setting, and had at least a
             12-month disease-free interval since the end of their last cytotoxic therapy, were
             eligible for the study

          -  Participants who received prior hormonal therapy, or no more than 1 cytotoxic
             chemotherapy regimen (anthracyclines, taxanes, or antitubulin agents were not
             permitted), or both for advanced disease

          -  Participants with normal cardiac function, as evidenced by a normal left ventricular
             ejection fraction

        Exclusion Criteria:

          -  More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer

          -  Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel,
             vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen
             that included alkylating agents or antimetabolite agents was acceptable)

          -  Less than 2 months since the last dose of trastuzumab

          -  Less than 3 weeks since last dose of tamoxifen or fulvestrant, or less than 1 week
             since the last dose of other hormonal therapy

          -  Radiation to areas of disease within 30 days before study enrollment

          -  History of New York Heart Association Class II or greater cardiac disease or other
             clinical evidence of congestive heart failure
Clinical trial NCT00346047 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: placebo, buprenorphine transdermal system
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females age 20 years or older.

          -  Clinical diagnosis of low back pain for 4 weeks or longer with non-malignant pain
             etiology.

        Exclusion Criteria:

          -  Subjects who have a current chronic disease(s) or who have a past history and high
             possibilities to relapse, in addition to low back pain, requiring frequent analgesic
             therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, osteoarthritis and
             diabetic neuropathy).
Clinical trial NCT00077714 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Double-blind phase: DSM-IV diagnosis of schizophrenia for at least 1 year

          -  experiencing an acute episode, with a total PANSS score at screening between 70 and
             120

          -  agree to voluntary hospitalization for a minimum of 14 days. Open-label phase: must
             have completed the 6 weeks of double-blind treatment or completed at least 21 days of
             treatment and discontinued due to lack of efficacy.

        Exclusion Criteria:

          -  DSM-IV axis I diagnosis other than schizophrenia

          -  DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation
             (nicotine and caffeine dependence are not exclusionary)

          -  history of neuroleptic malignant syndrome (NMS)

          -  history of any severe preexisting gastrointestinal narrowing (pathologic or
             iatrogenic)

          -  previous history of lack of response to risperidone when acutely psychotic

          -  significant risk of suicidal or violent behavior.
Clinical trial NCT00393042 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: dexmethylphenidate, mixed amphetamine salts, er, placebo
SMILES: [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1, C[C@H](N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Any ADHD subtype, determined by KSADS interview (Kaufman, Birmaher et al. 1997).
             Comorbidity will likewise be allowed, to ensure representation.

          -  Signed informed consent and assent

          -  Clinical Global Impressions - Severity for ADHD (CGI-S-ADHD) rating is greater than or
             equal to 4

          -  Findings on physical exam, laboratory studies, vital signs, and ECG are judged to be
             normal for age

          -  Pulse and blood pressure are within 95% of age and gender mean

          -  Able to complete study instruments and swallow capsules

          -  Willing to commit to the entire visit schedule for the study, including at least one
             visit to UIC Medical Center.

        Exclusion Criteria:

          -  Previous diagnosis of mental retardation

          -  Non-responder to either medication at the doses offered in the study in an adequate
             trial

          -  Must not have experienced disabling adverse effects with either medication

          -  Concomitant psychotropic medications are required or medications which might have a
             CNS effect

          -  Any other medical condition which represents a contraindication for either treatment
             is present

          -  History of alcohol or drug abuse in the past 3 months, or a positive urinary toxic
             screen on initial evaluation that is not explained by a time-limited medical
             circumstance

          -  Females of childbearing age who are sexually active, do not use acceptable birth
             control (double protection method), and after counseling, are unwilling to do so

          -  History of allergic reactions to multiple medications

          -  A history of psychosis

          -  Diagnosis of bipolar disorder
Clinical trial NCT01077362 (phase 3, status: completed)
Conditions: arthritis, psoriatic
ICD codes: L40.52
Drugs: placebo, ustekinumab 45 mg, ustekinumab 90 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have had a documented diagnosis of psoriatic arthritis (PsA) at least 6 months

          -  Have a diagnosis of active PsA at the time of entry into the study with at least 5
             tender and 5 swollen joints at baseline

          -  May have previously received at least 8 weeks of etanercept, adalimumab, golimumab or
             certolizumab pegol or at least 14 weeks of infliximab or proven inability to tolerate
             anti-TNF therapy for 8-14 weeks

          -  If the patient is using methotrexate, they should have started treatment at a dose not
             to exceed 25 mg/week at least 3 months prior to the beginning of the study and should
             have no serious toxic side effects attributable to methotrexate

        Exclusion Criteria:

          -  Have other inflammatory diseases, including but not limited to rheumatoid arthritis,
             ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease

          -  Have used any therapeutic agent targeted at reducing IL-12 or IL-23, including but not
             limited to ustekinumab and ABT-874

          -  Have used infliximab, golimumab or certolizumab pegol within 12 weeks of first study
             drug injection, or etanercept or adalimumab within 8 weeks of first study drug
             injection

          -  Have a medical history of latent or active granulomatous infection, including TB,
             histoplasmosis, or coccidioidomycosis, prior to screening

          -  Have any known malignancy or have a history of malignancy (with the exception of basal
             cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in
             situ that has been treated with no evidence of recurrence, or squamous cell carcinoma
             of the skin that has been treated with no evidence of recurrence within 5 years of the
             beginning of the study
Clinical trial NCT00289263 (phase 3, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent.

          -  Patients with metastatic breast cancer in response or stable disease after six to
             eight courses of first line induction chemotherapy treatment

          -  Measurable and/or evaluable disease

          -  Performance status ECOG 0, 1, 2.

          -  Normal cardiac function, confirmed by left ventricular ejection fraction (LVEF).

        Exclusion Criteria:

          -  Presence of peripheral neuropathy > grade 2 by NCI Common Toxicity Criteria (NCI-CTC)
             following induction chemotherapy

          -  Adjuvant taxane-based therapy
Clinical trial NCT01343680 (phase 3, status: terminated)
Conditions: childhood cancer, aplastic anemia, metabolic disorders
ICD codes: F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2, D61.3, D61.9, D61.09, D61.1, D61.2, D61.89, E88.9, O03.33, O04.83, O03.83, O07.33, E88.89, E89.89
Drugs: heparin, normal saline
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O, O
Reason stopped: 
    poor patient accrual
  
Eligibility criteria:

        Inclusion Criteria

          -  Diagnosis of any malignant or nonmalignant disease that requires a single lumen
             Broviac or double lumen Hickman-type CVC for the purpose of chemotherapy, blood
             product support or hematopoietic stem cell transplantation.

          -  CVC is planned to remain in situ for 6 months from study entry

        Exclusion Criteria:

          -  Thrombophilia (e.g. Factor V Leiden mutation, antiphospholipid syndrome) or previous
             thrombosis requiring anticoagulation (e.g. enoxaparin, unfractionated heparin)

          -  Bleeding disorder (e.g. von Willebrand's disease, hemophilia)

          -  Previous CVC that was removed due to any complication
Clinical trial NCT00455520 (phase 3, status: completed)
Conditions: diabetic neuropathy
ICD codes: E10.40, E11.40, E13.40, E10.43, E11.43, E13.43, E08.40
Drugs: cg5503, placebo
SMILES: CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Type 1 or Type 2 diabetes mellitus must have a documented clinical
             diagnosis of painful diabetic peripheral neuropathy with symptoms and signs for at
             least 6 months, and pain present at the time of screening

          -  The investigator considers the patient's blood glucose to be controlled by diet, or
             hypoglycemics, or insulin for at least 3 months prior to enrolling in the study (this
             control should be documented by figures of glycated hemoglobin [HbA1c] no greater than
             11% at screening)

          -  Patients have been taking analgesic medications for the condition for at least 3
             months prior to screening (patients taking opioid analgesics must be dissatisfied with
             current treatment, and patients taking non-opioid analgesics must be dissatisfied with
             current analgesia)

          -  Patients currently requiring opioid treatment must be taking daily doses of an
             opioid-based analgesic equivalent to <=160 mg of oral morphine

        Exclusion Criteria:

          -  No significant pulmonary, gastrointestinal, endocrine, metabolic (except diabetes
             mellitus), neurological, psychiatric disorders (resulting in disorientation, memory
             impairment or inability to report accurately as in schizophrenia, Alzheimer's
             disease), or any other clinically significant disease that in the Investigator's
             opinion may affect efficacy or safety assessments or may compromise patient's safety
             during trial participation

          -  no history of moderate to severe hepatic impairment such as chronic hepatitis B or C,
             presence of active hepatitis B or C within the last 3 months or impaired hepatic
             function with ALT or AST greater than 3-fold ULN

          -  No patients with severely impaired renal function

          -  No laboratory values above or below limits of normal unless considered not clinically
             relevant by the Investigator

          -  No significant cardiac disease (e.g., unstable angina pectoris, angina pectoris
             Canadian Cardiovascular Society (CCS) class III-IV, acute myocardial infarction within
             the last 3 months, cardiac insufficiency New York Heart Association (NYHA) class
             III-IV) or significant vascular disease (e.g., peripheral arterial occlusive disease
             (PAOD) Fontaine class IIb-IV)

          -  no life-long history of seizure disorders or epilepsy
Clinical trial NCT01095445 (phase 3, status: terminated)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: peginterferon alfa-2b (pegetron) plus ribavirin (rebetol)
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Reason stopped: 
    unlikely to recruit the adequate number of patients within a reasonable timeline
  
Eligibility criteria:

        Inclusion Criteria:

          -  Infected with only genotype 3, hepatitis C

          -  Treatment naïve before current course of therapy

          -  A positive HCV RNA test result at Week 4 (no RVR)

          -  A negative HCV RNA test result at Week 12 (cEVR)

          -  A recent liver biopsy (within 3 years prior to study entry) is required. If the
             patient has either liver biopsy proven cirrhosis in the past or has splenomegaly with
             features of cirrhosis on ultrasound and/or thrombocytopenia (<150x109/ml) at any time
             in the past or has a Fibroscan reading of 10 or above or has a Fibrotest score of 0.75
             or above (equivalent to F3 on the METAVIR scale), a biopsy will not be required. A
             copy of the latest report must be available.

        Exclusion Criteria:

          -  Under age 18

          -  Co-infection with HIV or Hepatitis B or any other HCV genotype in addition to genotype
             3

          -  Prior treatment for Hepatitis C aside from herbal remedies

          -  Evidence of decompensated liver disease, such as ascites, bleeding varices, hepatic
             encephalopathy or jaundice (conjugated hyperbilirubinemia)

          -  INR > 1.3 at baseline

          -  Platelet count <70 X 109/μl at baseline

          -  Those subjects with diabetes and/or systemic hypertension will need to have ocular
             examinations (as per standard of care [SOC]) prior to treatment and will be excluded
             if they are found to have a diabetic retinopathy, optic nerve disorders, retinal
             hemorrhage or any other clinically significant abnormality

          -  Pre-existing psychiatric conditions including:

               -  Current moderate or severe depression despite appropriate therapy.

               -  Active suicidal ideation or previous attempt at suicide

               -  Patients with a history of severe psychiatric disorder (may be included if so
                  desired by the investigator but pretreatment psychiatric evaluation is required
                  (SOC)).

               -  Clinical diagnosis of current substance abuse: Alcohol (>40g/d), injection drugs,
                  inhalational drugs (not including marijuana), psychotropics, narcotics, cocaine
                  use, prescription or over the counter drugs within one year of the screening
                  visit.
Clinical trial NCT00085748 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Double-Blind Phase: 65 years of age or older

          -  DSM-IV diagnosis of schizophrenia for at least 1 year

          -  total PANSS score at screening and baseline between 70 and 120, inclusive

          -  agrees to hospitalization for a minimum of 14 days and for the duration of the study,
             if clinically indicated

          -  Open-label treatment phase: completed 6 weeks of the double-blind treatment phase or
             finished at least 21 days of treatment and discontinued because of lack of efficacy.

        Exclusion Criteria:

          -  DSM-IV Axis I diagnosis other than schizophrenia

          -  DSM-IV diagnosis of substance dependence within the 6 months before screening
             (nicotine and caffeine dependence are not exclusionary)

          -  history of tardive dyskinesia or neuroleptic malignant syndrome (NMS)

          -  history of any severe preexisting severe gastrointestinal narrowing (pathologic or
             iatrogenic)

          -  previous history of a lack of response (2 adequate trials) to any antipsychotic